

## DAFTAR PUSTAKA

1. Hadiansyah T, Pragholapat A. Kecemasan Keluarga Dalam Merawat Klien Skizofrenia. *J Keperawatan 'Aisyiyah*. 2020;7(1):25–9.
2. Suhery D. Analisis Efektifitas-Biaya Penggunaan Antipsikiotik Kombinasi Quetiapin+Risperidon Pada Pasien Rawat Inap Dengan Skizofrenia Paranoid Di Rumah Sakit Jiwa PROF HB Saanin Padang. Universitas Andalas; 2023.
3. Andari S, Besar B, Dan P, Pelayanan P, Sosial K. Pelayanan Sosial Panti Berbasis Agama dalam Merehabilitasi Penderita Skizofrenia. *J PKS*. 2017;16(2):195–208.
4. Zahnia S, Wulan Sumekar D. Kajian Epidemiologis Skizofrenia. *Majority*. 2016;5(5):160–6.
5. Kemenkes R.I. Peraturan Menteri Kesehatan Nomor 27 Tahun 2014 Tentang Petunjuk Teknis Sistem INA CBGs. 2014;
6. Istichomah, R F. the Effectiveness of Family Knowledge About Schizophrenia Toward Frequency of Recurrence of Schizophrenic Family Members At Poly Mental Grhasia Mental Hospital D. I. Yogyakarta. *J Kesehat Samora Ilmu*. 2019;10(2):1689–99.
7. Landra IKG, Anggelina KDI. Skizofrenia Paranoid. *Ganesha Med J*. 2022;2(1):66–71.
8. Praveena Y, Sandhya KH, Ram GM, Bhuvan KC, Harinadha Baba K, Shaik K. Cost-Effectiveness Analysis of Olanzapin and Risperidon in Schizophrenic Patients in The Indian Healthcare Settings Of Andhra Pradesh, India. *J Pharm Heal Serv Res*. 2020;11(3):223–9.
9. Suwarni & Rahayu DA. Peningkatan Kemampuan Interaksi Pada Pasien Isolasi Sosial Dengan Penerapan Terapi Aktivitas Kelompok Sosialisasi Sesi 1-3. *Ners Muda*. 2020;1(1):11–7.
10. Damanik RK, Pardede JA& MLW. Terapi Kognitif Terhadap Kemampuan Interaksi Pasien. *J Ilmu Keperawatan dan Kebidanan*. 2020;11(2):226–35.
11. Desai PR, Lawson KA, Barner JC, Rascati KL. Estimating the Direct and Indirect Costs For Community-Dwelling Patients With Schizophrenia. *J Pharm Heal Serv Res*. 2013;4(4):187–94.
12. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. *Lancet*. 2016;388(10039):86–97.
13. Suhery D, Sari YO, Fitria N. Analisa Hubungan Biaya Total dan Lama Rawatan Penggunaan Risperidon dan Quetiapin pada Pasien Skizofrenia Paranoid di RS Jiwa Prof HB Saanin Padang. *J Farm Higea [Internet]*. 2023;15(1). Available from: [www.jurnalfarmasihigea.org](http://www.jurnalfarmasihigea.org)
14. NUR SAB. Profil Pasien Skizofrenia DI RSJ PROF HB Saanin Pada Tahun 2016. [Padang]: Universitas Andalas; 2017.
15. Orrico-Sánchez A, López-Lacort M, Muñoz-Quiles C, Sanfélix-Gimeno G,

- Diéz-Domingo J. Epidemiology of Schizophrenia and its Management Over 8-Years Period Using Real-World Data in Spain. *BMC Psychiatry*. 2020;20(1):1–9.
16. Stuart G. *Buku Saku Keperawatan Jiwa*. Jakarta: EGC; 2013.
  17. Kementrian Kesehatan. *Pedoman Pelayanan Kefarmasian Untuk Pasien Gangguan Jiwa*. Jakarta: Kementerian Kesehatan RI; 2021.
  18. Kaplan & Sadock. *Synopsis Of Psychiatry: Behavioral Scienes/Cinical/Psychiatri-Elevent Edition*. 11th ed. LWW; 2015.
  19. Damaiyanti & Iskandar. *Asuhan Keperawatan Jiwa*. Bandung: Refika Aditama; 2014.
  20. FR, Cahyaningsih & Habibi Nasution S. Skizofrenia Hebefrenik. *MAJORITY*. 2019;8:2017–20.
  21. Medica M. Laporan Kasus Dinamika Psikologis Pasien Skizofrenia Residual : Laporan Kasus Jeanete Ophilia Papilaya FKIP Universitas Pattimura. *Molucca Medica*. 2019;12:25–33.
  22. Fachrudin D. Skizofrenia Simpleks. *Tunas Med*. 2019;(August).
  23. Hendarsyah F. Diagnosis dan Tatalaksana Skizofrenia Paranoid dengan Gejala-Gejala Positif dan Negatif. *J Medula Unila*. 2016;4(3):57–62.
  24. Hawari Haji D. *Skizofrenia Edisi Ketiga Pendekatan Holistik (BPSS) Bio-Psiko-Sosial Spiritual*. Jakarta. Badan Penerbit Fakultas Kedokteran UI; 2012.
  25. Wahyudi A, Fibriana AI. Faktor Resiko Terjadinya Skizofrenia (Studi Kasus di Wilayah Kerja Puskesmas Pati II). *Public Heal Perspect J*. 2016;1(1):1–12.
  26. Teifion D. *ABC Kesehatan Mental*. Jakarta: EGC; 2009.
  27. Purwandityo AG, Febrianti Y, Sari CP. The Influence of Antipsychotic to Decrease the Score of The Positive and Negative Syndrome Scale-Excited Component. 2018;7(1).
  28. Yuyun Yulianti S. Cetak biru pelayanan pasien di Rumah Sakit jiwa provinsi jawa barat tahun 2014. *J Adm Kebijak Kesehat*. 2014;1 Nomor 2:87–95.
  29. Purwandityo AG, Febrianti Y, Sari CP, Ningrum VDA, Sugiyarto OP. The Influence of Antipsychotic to Decrease the Score of The Positive and Negative Syndrome Scale-Excited Component. *Indones J Clin Pharm*. 2018;7(1):19–29.
  30. Montoya A, Valladares A, Lizán L, San L, Escobar R, Paz S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. *Health Qual Life Outcomes*. 2011;9(1):18.
  31. RI KK. *Pedoman Nasional Pelayanan Kedokteran Jiwa*. Jakarta: Kementerian Kesehatan RI; 2015.

32. Joseph T. DiPiro, Gary C. Yee, L. Michael Posey, Stuart T. Haines, Thomas D. Nolin VE. *Pharmacotherapy: A Pathophysiologic Approach*, 11e. Vol. 50, Medicine (United Kingdom). McGraw Hill; 2020.
33. Boman L, De Butte M. Neurobehavioral Effects of Chronic Low-dose Risperidon Administration in Juvenile Male Rats. *Behav Brain Res.* 2019;363(January):155–60.
34. PDSKJI. *Konsensus Penatalaksanaan Gangguan Skizofrenia*. PDSKJI, editor. Jakarta: PDSKJI; 2011.
35. Scruth E. Risperidon for Psychosis-Induced Aggression or Agitation. *Issues Ment Health Nurs.* 2019;40(11):988–9.
36. Madaan V, Bestha DP, Kolli V, Jauhari S, Burket RC. Clinical Utility Of The Risperidon Formulations in The Management Of Schizophrenia. *Neuropsychiatr Dis Treat.* 2011;7(1):611–20.
37. National Center for Biotechnology Information. PubChem Compound Summary for CID 5073, Risperidon. 2024;
38. Zubiaur P, Soria-Chacartegui P, Villalpos-García G, Gordillo-Perdomo JJ, Abad-Santos F. The Pharmacogenetics of Treatment With Olanzapin. *Pharmacogenomics.* 2021;22(14):939–58.
39. Information NC for B. PubChem Compound Summary for CID 135398745, Olanzapin. 2024;
40. Fitria N. *Pedoman Pembuatan Review Sistematis di Bidang Ekonomi Kesehatan*. Padang: Andalas University Press; 2020.
41. RI KK. *Buku Panduan Penilaian Teknologi Kesehatan Efektivitas Klinis dan Evaluasi Ekonomi*. Jakarta: Kemenkes RI; 2017.
42. Kemenkes RI. *Pedoman Penerapan Kajian Farmakoekonomi*. Jakarta: Kementerian Kesehatan RI; 2013.
43. Kemenkes RI. *Pedoman Umum Penilaian Teknologi Kesehatan Di Indonesia*. *Angewandte Chemie International Edition*, 6(11), 951–952. 2022. 5–24 p.
44. Fitria N. *Analisis Farmakoekonomi Penggunaan Kombinasi Metformin Dan Glimpiride: A Cost-Effectiveness Analysis* [Internet]. Yogyakarta: Pustaka Egaliter; 2023. Available from: <http://www.nber.org/papers/w16019>
45. Suhadi R. *SELUK Beluk Hipertensi : Peningkatan Kompetensi Klinis Untuk Pelayanan Kefarmasian*. Yogyakarta: Sanata Dharma University Press; 2016.
46. O'Mahony JF, Newall AT, van Rosmalen J. Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice. *Pharmacoeconomics.* 2015;33(12):1255–68.
47. Sri Novitayani. Karakteristik Pasien Skizofrenia Dengan Riwayat Rehospitalisasi. *Idea Nurs J.* 2016;VII(2):23.
48. Kulkarni J, Gavrilidis E, Worsley R, Rheenen T Van, Hayes E. The role of estrogen in the treatment of men with schizophrenia. *Int J Endocrinol Metab.*



- 2013;11(3):129–36.
49. Handayani L, Febriani F, Rahmadanni A, Saufi A. Faktor Risiko Kejadian Skizofrenia Di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (Diy). *Humanitas (Monterey N L)*. 2017;13(2):135.
  50. Oken. Patterns of Stress in Schizophrenia. *Psychiatry Res [Internet]*. 2008;23(1):1–7.
  51. Darsana IW, Suariyani NLP. Trend Karakteristik Demografi Pasien Skizofrenia Di Rumah Sakit Jiwa Provinsi Bali (2013-2018). *Arch Community Heal*. 2020;7(1):41.
  52. Weiser M, Werbeloff N, Vishna T, Yoffe R, Lubin G, Shmushkevitch M, et al. Elaboration on immigration and risk for schizophrenia. *Psychol Med*. 2008;38(8):1113–9.
  53. Tang Y lang, Gillespie CF, Epstein MP, Mao P xian, Jiang F, Chen Q, et al. Gender differences in 542 Chinese inpatients with schizophrenia. *Schizophr Res*. 2007;97(1–3):88–96.
  54. Domenech C, Bernasconi C, Moneta MV, Nordstroem AL, Cristobal-Narvaez P, Vorstenbosch E, et al. Health-related quality of life associated with different symptoms in women and in men who suffer from schizophrenia. *Arch Womens Ment Health*. 2019;22(3):357–65.
  55. Angermeyer MC, Kühn L, Goldstein JM. Gender and the course of schizophrenia: Differences in treated outcomes. *Schizophr Bull*. 1990;16(2):293–307.
  56. McLay RN, Daylo A, Hammer PS. Predictors of Length of Stay in a Psychiatric Ward Serving Active Duty Military and Civilian Patients. *Mil Med*. 2005;170(3).
  57. Smith TF, Hirdes JP. Predicting Social Isolation Among Geriatric Psychiatry Patients. *Int Psychogeriatrics*. 2009;21(1).
  58. Zilber N, Popper M, Lerner Y. Patterns and Correlates of Psychiatric Hospitalization in a Nationwide Sample. II. Correlates of Length of Hospitalization and Length of Stay Out of Hospital. *Soc Psychiatry Psychiatr Epidemiol*. 1990;25(3).
  59. Macpherson R, Jerrom B, Hughes A. A Controlled Study of Education About Drug Treatment in Schizophrenia. *Br J Psychiatry*. 1996;168.
  60. Rissa MM, Darmawan E. Nilai PANSS-EC Dan GAF Pada Pasien Gangguan Mental Psikotik Yang Diterapi Atypical-Atypical Dan Atypical-Typical Di Rumah Sakit Jiwa Grhasia Yogyakarta. *Pharm J Islam Pharm*. 2021;5(1):15.
  61. Sadock BJ, Sadock VA. Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 10th edition. *Indian J Psychiatry*. 2009;51(4).
  62. Kemenkes RI. Buku Panduan Penilaian Teknologi Kesehatan Efektivitas Klinis dan Evaluasi Ekonomi. 2017;p 1-44.
  63. Lubinga SJ, Mutamba BB, Nganizi A, Babigumira JB. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. *Appl*

Health Econ Health Policy. 2015;13(5):493–506.

64. Ranti I, Octaviany AF, Kinanti S. Analisis Efektivitas Terapi dan Biaya antara Haloperidol Kombinasi dengan Risperidon Kombinasi pada Terapi Skizofrenia Fase Akut. *J Mutiara Med.* 2015;15(1):57–64.
65. Abdulah R, Siregar RF, Alfian SD. Cost-effectiveness Analysis of Antipsychotic Combination Therapy in Schizophrenia Inpatients. *Indones J Clin Pharm.* 2017;6(1):61–6.
66. García-ruiz AJ, Pérez-costillas L, Montesinos AC, Alcalde J, Oyagüez I, Casado MA. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. 2012;
67. Andriani Y, Septiani FN, Defirson D. Cost-effectiveness of Antipsychotics in Treatment of Schizophrenia Patients admitted to a secondary Hospital. *Indones J Pharm Clin Res.* 2019;2(2):43–52.
68. Kurnia Utami I, Barliana MI, Halimah E. Cost Analysis of Antipsychotics Schizophrenia of Inpatients in Mental Hospital West Java Province. *J Farm Galen (Galenika J Pharmacy).* 2022;8(2):143–53.
69. Nety Daud Karaeng, Andi Ilham Makhmud KL. Analisis Efektivitas Biaya Penggunaan Risperidon Kombinasi Dan Haloperidol Kombinasi Pada Pasien Skizofrenia Di Rsj. Dr. V. L. Ratumbusang Provinsi Sulawesi Utara. *Maj Farm dan Farmakol.* 2019;22(3):69–72.
70. Aryani.F. E a. Cost-Effectiveness Analysis and Efficacy Of Antipsychotes Therapy Of Haloperidol-Chlorpromazine in Schizophrenia Patients. *PHARMACY, Vol14 No 01 Juli 2017.* 2017;14(01):98–107.
71. Manso de Mello Vianna C, Ribeiro Alves Fernandes R, Bittencourt Gonzalez Mosegui G, Queiroz Pagnin V. Cost-effectiveness analysis and budgetary impact of antipsychotics available in the Brazilian Unified Health System. *J Bras Econ da Saúde.* 2020;12(3):195–205.

